{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-026140","form_type":"8-K/A","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.876610+00:00","generated_at":"2026-06-01T06:47:14.484136+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avalo Therapeutics completes acquisition of AlmataBio; discloses audited financials and pro forma info","bullets":["AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.","Acquired anti-IL-1β asset (AVTX-009) from Leap Therapeutics for $500k cash plus potential milestones up to $70M development/regulatory and $720M sales-based.","Deal closed March 27, 2024, structured as stock-for-stock: AlmataBio equity exchanged for Avalo common and non-voting convertible preferred stock.","Unaudited pro forma combined statements for year ended Dec 31, 2023 and Q1 2024 filed as Exhibit 99.2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-026140","json":"https://secwatch.observer/filing/0001628280-24-026140.json","markdown":"https://secwatch.observer/filing/0001628280-24-026140.md","text":"https://secwatch.observer/filing/0001628280-24-026140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/0001628280-24-026140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/avtx-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:47:14.484136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}